Investing16d
Virax Biolabs shares T-Cell dysfunction findings
LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis, has ...
Investing16d
Virax Biolabs shares T-Cell dysfunction findings
LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis ...
Yahoo Finance16d
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
LONDON, March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and ...
Yahoo Finance24d
Virax Biolabs to Present at 19th World Immune Regulation Meeting
About Virax Biolabs Group Limited Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs ...
Wall Street Journal29d
Virax Biolabs Group Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Barron's5mon
Virax Biolabs Group Ltd.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Investing2y
Virax Biolabs Group Ltd (VRAX)
Virax Biolabs Group Limited (VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States ...